Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 5Recruiting 3Terminated 2Completed 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 10Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Recurrence 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1HER2-positive Breast Cancer 1Gastroesophageal Junction Cancer 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Carcinoma, Squamous Cell 1Advanced Solid Tumors 1Advanced Pancreatic Cancer 1Advanced Non-small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1Advanced Malignant Neoplasm 1Advanced Esophageal Carcinoma 1Advanced Breast Cancer 1

Interventions

pyrotinib 5Trastuzumab 4pertuzumab 2neratinib 1exemestane 1dalpiciclib 1Paclitaxel 1Leuprolide 1Goserelin 1Fulvestrant 1Docetaxel 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × HER2-positive Breast Cancer × Docetaxel × Clear all
NCT07116824 2025-08-12

HB1801 Combined Treatment of HER2-positive Breast Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Not yet recruiting
80 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡